Back to Journals » Neuropsychiatric Disease and Treatment » Volume 15
Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives
Authors Askalsky P, Iosifescu DV
Received 4 July 2019
Accepted for publication 26 October 2019
Published 22 November 2019 Volume 2019:15 Pages 3255—3272
DOI https://doi.org/10.2147/NDT.S188906
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Melinda Thomas
Peer reviewer comments 3
Editor who approved publication: Dr Roger Pinder
Paula Askalsky,1 Dan V Iosifescu1,2
1Department of Psychiatry, NYU Langone School of Medicine, New York, NY, USA; 2Clinical Research Division, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA
Correspondence: Dan V Iosifescu
Department of Psychiatry, NYU School of Medicine, One Park Avenue, 8th Floor, New York, NY 10016, USA
Tel +1 646-754-5156
Email Dan.Iosifescu@nyumc.org
Abstract: Major depressive disorder (MDD) is a prevalent condition associated with high rates of disability, as well as suicidal ideation and behavior. Current treatments for MDD have significant limitations in efficacy and side effect burden. FDA-approved devices for MDD are burdensome (due to repeated in-office procedures) and are most suitable for severely ill subjects. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. In this paper, we review a novel neuromodulation strategy, transcranial photobiomodulation (t-PBM) with near-infrared light (NIR). The scope of our review includes the known biological mechanisms of t-PBM, as well as its efficacy in animal models of depression and in patients with MDD. Theoretically, t-PBM penetrates into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow. Animal and human studies, using a variety of t-PBM settings and experimental models, suggest that t-PBM may have significant efficacy and good tolerability in MDD. In aggregate, these data support the need for large confirmatory studies for t-PBM as a novel, likely safe, and easy-to-administer antidepressant treatment.
Keywords: low-level light therapy, photobiomodulation, near infrared radiation, major depressive disorder, depression
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.